Skip to main content
Premium Trial:

Request an Annual Quote

Intradigm Licenses siRNA IP from UMass Medical School

NEW YORK (GenomeWeb News) – Intradigm has licensed siRNA technology from the University of Massachusetts Medical School that will help in its RNAi-based therapeutics programs, the company said today.
 
The UMass intellectual property covers “certain efficacy-enhancing structural elements” of siRNA, as well as parameters for structural modifications that will help the company “significantly improve the potency and efficacy of RNAi therapeutics,” Intradigm said.
 
The Palo Alto, Calif.-based company said its RNAi NPX delivery technology carries active siRNA molecules that can help improve circulation half life and selective distribution to targeted tissue.
 
The company’s multi-targeted therapeutics can silence several mRNAs representing parallel or synergistic elements of the same disease pathway, Intradigm said.
 
Financial terms of the agreement were not released.

The Scan

Looking for Omicron

NPR reports that SARS-CoV-2 testing in the US has gotten better but also that some experts say more needs to be done to better track the Omicron variant.

Holmes Alleges Abuse

The Associated Press reports that Theranos' Elizabeth Holmes has testified at her wire fraud trial that her business and romantic partner abused her.

Bit More Diverse, But More to Do

While Black and Hispanic patients are more likely to participate in cancer clinical trials than previously, they are still underrepresented, according to US News & World Report.

PNAS Papers on Yeast Gene Silencing, Zika Virus Inhibition, Immunoglobulin Hypermutation

In PNAS this week: gene silencing in Saccharomyces cerevisiae, possible neuroprotective role for SHFL in a mouse model of Zika virus infection, and more.